Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from 4DMedical Ltd ( (AU:4DX) ).
4DMedical Limited is hosting an exclusive webinar featuring Dr. Kyle Hogarth, a renowned pulmonologist, to discuss the clinical applications and benefits of 4DMedical’s respiratory imaging technology. This session aims to provide shareholders with insights into the company’s innovative products and their impact on lung care, highlighting the advantages over traditional diagnostic methods and the future of respiratory imaging.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$1.05 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited (ASX:4DX) is a global medical technology company specializing in advanced imaging and artificial intelligence for respiratory care. The company offers a suite of software solutions, including the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), designed to enhance diagnostic precision and integrate seamlessly into hospital systems through a Software-as-a-Service (SaaS) model. With its recent acquisition of Imbio, 4DMedical is at the forefront of redefining respiratory disease management worldwide.
Average Trading Volume: 5,241,554
Technical Sentiment Signal: Buy
Current Market Cap: A$861.3M
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.